These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34718074)

  • 1. Opportunities and challenges related to saturation of toxicokinetic processes: Implications for risk assessment.
    Tan YM; Barton HA; Boobis A; Brunner R; Clewell H; Cope R; Dawson J; Domoradzki J; Egeghy P; Gulati P; Ingle B; Kleinstreuer N; Lowe K; Lowit A; Mendez E; Miller D; Minucci J; Nguyen J; Paini A; Perron M; Phillips K; Qian H; Ramanarayanan T; Sewell F; Villanueva P; Wambaugh J; Embry M
    Regul Toxicol Pharmacol; 2021 Dec; 127():105070. PubMed ID: 34718074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating human exposure information in a weight of evidence approach to inform design of repeated dose animal studies.
    Lowe K; Dawson J; Phillips K; Minucci J; Wambaugh JF; Qian H; Ramanarayanan T; Egeghy P; Ingle B; Brunner R; Mendez E; Embry M; Tan YM
    Regul Toxicol Pharmacol; 2021 Dec; 127():105073. PubMed ID: 34743952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the kinetically-derived maximum dose concept in selection of top doses for toxicity studies hampers proper hazard assessment and risk management.
    Heringa MB; Cnubben NHP; Slob W; Pronk MEJ; Muller A; Woutersen M; Hakkert BC
    Regul Toxicol Pharmacol; 2020 Jul; 114():104659. PubMed ID: 32334038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of diurnal systemic dose of agrochemicals in regulatory toxicity testing--an integrated approach without additional animal use.
    Saghir SA; Bartels MJ; Rick DL; McCoy AT; Rasoulpour RJ; Ellis-Hutchings RG; Sue Marty M; Terry C; Bailey JP; Billington R; Bus JS
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):321-32. PubMed ID: 22440553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rethinking guideline toxicity testing.
    Saghir SA
    Regul Toxicol Pharmacol; 2015 Jul; 72(2):423-8. PubMed ID: 25980640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing maximum tolerated doses for a 2-year combined chronic/carcinogenicity rat study based on toxicokinetic and toxicity gender differences.
    Liu Z; Wasniewski A; Lamperti S; Mainolfi K; Chandrasekaran A
    Regul Toxicol Pharmacol; 2017 Nov; 90():153-159. PubMed ID: 28888958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principles of dose-setting in toxicology studies: the importance of kinetics for ensuring human safety.
    Borgert CJ; Fuentes C; Burgoon LD
    Arch Toxicol; 2021 Dec; 95(12):3651-3664. PubMed ID: 34623454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing a framework for integrating toxicokinetics into human health risk assessment for agrochemicals.
    Terry C; Hays S; McCoy AT; McFadden LG; Aggarwal M; Rasoulpour RJ; Juberg DR
    Regul Toxicol Pharmacol; 2016 Mar; 75():89-104. PubMed ID: 26472101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating toxicokinetics into toxicology studies and the human health risk assessment process for chemicals: Reduced uncertainty, better health protection.
    Claire T; Sean H
    Regul Toxicol Pharmacol; 2022 Feb; 128():105092. PubMed ID: 34863906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel approach to calculating the kinetically derived maximum dose.
    Burgoon LD; Fuentes C; Borgert CJ
    Arch Toxicol; 2022 Mar; 96(3):809-816. PubMed ID: 35103817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proper knowledge on toxicokinetics improves human hazard testing and subsequent health risk characterisation. A case study approach.
    Bessems JG; Geraets L
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):325-34. PubMed ID: 24051162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
    Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
    Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afidopyropen: Challenges and impact of a toxicokinetic study designed to identify a point of inflection from dose-proportionality.
    Loccisano AE; Freeman E; Riffle B; Doi A; Frericks M; Fegert I; Fabian E
    Regul Toxicol Pharmacol; 2021 Aug; 124():104962. PubMed ID: 34019964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.
    Adler S; Basketter D; Creton S; Pelkonen O; van Benthem J; Zuang V; Andersen KE; Angers-Loustau A; Aptula A; Bal-Price A; Benfenati E; Bernauer U; Bessems J; Bois FY; Boobis A; Brandon E; Bremer S; Broschard T; Casati S; Coecke S; Corvi R; Cronin M; Daston G; Dekant W; Felter S; Grignard E; Gundert-Remy U; Heinonen T; Kimber I; Kleinjans J; Komulainen H; Kreiling R; Kreysa J; Leite SB; Loizou G; Maxwell G; Mazzatorta P; Munn S; Pfuhler S; Phrakonkham P; Piersma A; Poth A; Prieto P; Repetto G; Rogiers V; Schoeters G; Schwarz M; Serafimova R; Tähti H; Testai E; van Delft J; van Loveren H; Vinken M; Worth A; Zaldivar JM
    Arch Toxicol; 2011 May; 85(5):367-485. PubMed ID: 21533817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment.
    Dixit R; Riviere J; Krishnan K; Andersen ME
    J Toxicol Environ Health B Crit Rev; 2003; 6(1):1-40. PubMed ID: 12587252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetically-derived maximal dose (KMD) indicates lack of human carcinogenicity of ethylbenzene.
    Burgoon LD; Borgert CJ; Fuentes C; Klaunig JE
    Arch Toxicol; 2024 Jan; 98(1):327-334. PubMed ID: 38059960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches of validation of a 2-week combined repeated oral dose toxicity study with plasma micro sampling toxicokinetics (PMS-TK) in common marmosets.
    Mochizuki H; Murota N; Sato SI; Nii K; Kouhei Y; Taniguchi M; Inoue R; Nishime C; Tsutsumi H
    J Toxicol Sci; 2018; 43(11):685-695. PubMed ID: 30405001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using toxicokinetic-toxicodynamic modeling as an acute risk assessment refinement approach in vertebrate ecological risk assessment.
    Ducrot V; Ashauer R; Bednarska AJ; Hinarejos S; Thorbek P; Weyman G
    Integr Environ Assess Manag; 2016 Jan; 12(1):32-45. PubMed ID: 25833822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicokinetics, dose-response, and risk assessment of nanomaterials: Methodology, challenges, and future perspectives.
    Chen Q; Riviere JE; Lin Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Nov; 14(6):e1808. PubMed ID: 36416026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.